Acadia Pharmaceuticals
ACAD Mid CapHealthcare · Biotechnology
Aggiornato: May 2, 2026, 22:05 UTC
Metriche Chiave
Analisi della Valutazione
Informazioni sull'Azienda
Acadia Pharmaceuticals Stock at a Glance
Acadia Pharmaceuticals (ACAD) is currently trading at 18,72 € with a market capitalization of 3,2 Mrd. €. The trailing P/E ratio stands at 9.54x, with a forward P/E of 23.03x. The 52-week range spans from 12,33 € to 24,18 €; the current price is 22.6% below the yearly high. Year-over-year revenue growth stands at +9.4%. The net profit margin stands at 36.49%.
💰 Dividendo
Acadia Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Raccomandazioni degli Analisti
20 analysts rate Acadia Pharmaceuticals (ACAD) on consensus: Comprare. The average price target is 27,04 €, implying +44.42% from the current price. Analyst price targets range from 14,50 € to 38,39 €.
Tesi di Investimento: Punti di Forza e Debolezze
- Profitable with 36.49% net margin
- High return on equity (39.89% ROE)
- High gross margin of 61.01% — indicates pricing power
- Analyst consensus: Buy
- Currently flagged as undervalued
- Solid balance sheet with low debt (D/E 4.25)
- –High short interest (10.04%)
- –Negative free cash flow
Panoramica Tecnica
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profilo di Rischio
The data points to relatively defensive market behavior, elevated short interest (10.04%).
Dati di Trading
Azioni Correlate nello Stesso Settore
Where can I buy Acadia Pharmaceuticals?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
